Total trials
1,395
Active
304
Phase 3
39
Total enrollment
996,348
Pipeline matrix
Showing 40 of 120 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ipilimumab | — | — | — | — | 7 | ||
| Guselkumab | — | — | — | 3 | |||
| Nivolumab | — | — | — | 6 | |||
| Bupivacaine | — | — | — | — | — | 3 | |
| Saline | — | — | — | 3 | |||
| Magnesium sulfate | — | — | — | — | 2 | ||
| Tranexamic Acid | — | — | — | — | 8 | ||
| Extended-Release Buprenorphine | — | — | — | — | — | 2 | |
| Sublingual Buprenorphine | — | — | — | — | — | 2 | |
| Aminocaproic acid | — | — | — | — | — | 2 | |
| IPACK block | — | — | — | — | — | 2 | |
| Relatlimab | — | — | — | — | — | 1 | |
| Evolocumab Cartridge | — | — | — | — | — | 1 | |
| Atorvastatin Calcium | — | — | — | — | — | 1 | |
| Ezetimibe | — | — | — | — | — | 1 | |
| 18F-FDG | — | — | — | — | — | 1 | |
| Thrombin | — | — | — | — | — | 1 | |
| Escitalopram Oxalate | — | — | — | — | — | 1 | |
| ACB | — | — | — | — | — | 1 | |
| Methylphenidate Hydrochloride Extended Release | — | — | — | — | — | 1 | |
| CpG-adjuvanted HBV Vaccine | — | — | — | — | — | 1 | |
| Traditional HBV Vaccine | — | — | — | — | — | 1 | |
| Herpes Zoster Subunit (HZ/su) Vaccine | — | — | — | — | — | 1 | |
| Lidocaine | — | — | — | 3 | |||
| Cannabidiol | — | — | — | — | 5 | ||
| Hydroxychloroquine | — | — | — | — | 5 | ||
| Dexamethasone | — | — | 6 | ||||
| 18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent | — | — | — | — | — | 1 | |
| IVIG | — | — | — | — | — | 1 | |
| Anticoagulant Therapy | — | — | — | — | — | 1 | |
| Psilocybin 25 mgs | — | — | — | — | — | 1 | |
| Niacin 100mg | — | — | — | — | — | 1 | |
| Nicotine Replacement Therapy Agent - Patches | — | — | — | — | — | 1 | |
| Nicotine Replacement Therapy Agent - Lozenges | — | — | — | — | — | 1 | |
| Nicotine Replacement Therapy Agent - Gum | — | — | — | — | — | 1 | |
| Continuous ketamine | — | — | — | — | — | 1 | |
| Ketamine + Saline | — | — | — | — | — | 1 | |
| Psilocybin | — | — | — | 7 | |||
| Tacrolimus | — | — | — | — | — | 3 | |
| Pembrolizumab | — | — | — | — | 8 |
80 more active programs hidden
Next readouts
- 2022-11-10
- 2022-12-29
- 2023-07-01
- 2025-04-18
- 2025-05-08
- 2025-05-28
- 2025-06-30
- 2025-08-31
- 2025-09-01
- 2025-10-30
Top conditions
- Breast Cancer36
- Hypertension35
- Prostate Cancer30
- Multiple Sclerosis26
- Obesity22
- Epilepsy21
- Cardiovascular Diseases19
- Diabetes16
Frequently asked questions about NYU Langone Health
- How many clinical trials does NYU Langone Health have on ClinicalTrials.gov?
- NYU Langone Health is listed as the lead sponsor on 1,395 clinical trials in ClinicalTrials.gov, 304 of which are currently active (recruiting, enrolling, or ongoing).
- How many of NYU Langone Health's trials are in Phase 3?
- 39 of NYU Langone Health's trials are in Phase 3, spread across 120 active drug programs.
- What therapeutic areas does NYU Langone Health focus on?
- NYU Langone Health's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Hypertension, Prostate Cancer, Multiple Sclerosis, Obesity.
- When are NYU Langone Health's next clinical trial readouts?
- NYU Langone Health has 10 upcoming primary-completion readouts tracked here; the soonest is “Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder”, expected around 2022-11-10.